Study aim: Comparison of Helicobacter pylori Eradication Rates Between 5-Day and 10-Day Levofloxacin-Based Triple Therapy Regimens Design: A phase 3, randomized, controlled, parallel-group clinical trial conducted on 120 patients with Helicobacter pylori infection confirmed by biopsy. The Excel RAND function was used for randomization. Settings and conduct: Study Setting: Ayatollah Rohani Hospital, Babol Methodology: Patients with confirmed H. pylori infection (via gastric biopsy) were randomly assigned to treatment groups. Participants/Inclusion and exclusion criteria: The inclusion criteria for this study consist of all individuals between 18 and 60 years of age with a histologically confirmed Helicobacter pylori infection who voluntarily consent to participate. The exclusion criteria : a history of prior H. pylori eradication therapy; severe or chronic diseases; pregnant women; recent use (within the past month) of NSAIDs, antibiotics, or proton pump inhibitors; previous gastric surgery; severe renal impairment (creatinine >2 mg/dL); significant hepatic dysfunction; gastric cancer; and hypersensitivity to any of the study medications (levofloxacin, amoxicillin, or pantoprazole). Intervention groups: The 5-day treatment group received amoxicillin 1 g twice daily, levofloxacin 500 mg (Tavanex®, Abidi Pharma) once daily and pantoprazole 40 mg (Abidi Pharma) twice daily for 5 days The 10-day treatment group received amoxicillin 1 g twice daily, levofloxacin 500 mg (Tavanex®, Abidi Pharma) once daily and pantoprazole 40 mg (Abidi Pharma) twice daily for 10 days Main outcome variables: H. pylori eradication rate, treatment-related adverse events, patient compliance rates.